Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
28 09 2022
28 09 2022
Historique:
received:
26
02
2022
accepted:
30
08
2022
entrez:
28
9
2022
pubmed:
29
9
2022
medline:
1
10
2022
Statut:
epublish
Résumé
By the end of July 2021, the majority of the Icelandic population had received vaccination against COVID-19. In mid-July a wave of SARS-CoV-2 infections, dominated by the Delta variant, spread through the population, followed by an Omicron wave in December. A booster vaccination campaign was initiated to curb the spread of the virus. We estimate the risk of infection for different vaccine combinations using vaccination data from 276,028 persons and 963,557 qPCR tests for 277,687 persons. We measure anti-Spike-RBD antibody levels and ACE2-Spike binding inhibitory activity in 371 persons who received one of four recommended vaccination schedules with or without an mRNA vaccine booster. Overall, we find different antibody levels and inhibitory activity in recommended vaccination schedules, reflected in the observed risk of SARS-CoV-2 infections. We observe an increased protection following mRNA boosters, against both Omicron and Delta variant infections, although BNT162b2 boosters provide greater protection against Omicron than mRNA-1273 boosters.
Identifiants
pubmed: 36171188
doi: 10.1038/s41467-022-33076-4
pii: 10.1038/s41467-022-33076-4
pmc: PMC9517986
doi:
Substances chimiques
Antibodies, Viral
0
RNA, Messenger
0
Vaccines, Synthetic
0
Viral Vaccines
0
mRNA Vaccines
0
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5701Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
Clin Infect Dis. 2021 Dec 16;73(12):2257-2264
pubmed: 33515252
Nature. 2021 Dec;600(7890):701-706
pubmed: 34673755
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
N Engl J Med. 2022 Feb 3;386(5):492-494
pubmed: 34965337
Nat Med. 2021 Sep;27(9):1530-1535
pubmed: 34312554
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
N Engl J Med. 2022 Mar 10;386(10):951-963
pubmed: 35045226
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2022 Feb 24;386(8):744-756
pubmed: 34986294
N Engl J Med. 2021 Dec 23;385(26):2413-2420
pubmed: 34879190
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Vaccine. 2021 Nov 26;39(48):6984-6989
pubmed: 34763949
N Engl J Med. 2021 Dec 23;385(26):2421-2430
pubmed: 34879188
Lancet. 2021 Jul 31;398(10298):385-387
pubmed: 34274038
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Lancet. 2022 Feb 26;399(10327):814-823
pubmed: 35131043
EBioMedicine. 2021 Jun;68:103410
pubmed: 34098342
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Med J Aust. 2021 Aug 16;215(4):149-151.e1
pubmed: 34296443
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nat Med. 2021 Sep;27(9):1525-1529
pubmed: 34262158